Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research led by Dr Mariana Borsa at the Kennedy Institute has found that a cellular housekeeping mechanism called autophagy plays a major role in ensuring that T cells generate diverse progenies upon cell division. The findings, published in Nature Cell Biology, could help boost vaccine response in older adults.

T stem cells normally undergo asymmetric cell division (left) whereby one daughter cell becomes a long-lived memory T cell. When autophagy is disrupted, both daughter cells inherit old mitochondria (red) and become effector T-cells.

When killer T cells of our immune system divide, they normally undergo asymmetric cell division (ACD): Each daughter cell inherits different cellular components, which drive the cells toward divergent fates – one cell becomes a short-lived fighter called an effector T cell, the other cell becomes a long-lived memory T cell.

Research by Dr. Mariana Borsa and Prof. Katja Simon, with important contributions from members of several labs at the Kennedy Institute of Rheumatology and other collaborators across Europe, has shown for the first time that cellular autophagy – a 'housekeeping' mechanism by which cells degrade and recycle cell cargo – plays a critical role in this decision process.

'Our study provides the first causal evidence that autophagy plays a central role in ensuring that T cells go through ACD normally. We found that when T stem cells divide, daughter cells inherit different mitochondria, which influences T cell fate decisions,' says Mariana. 'By understanding this process, we can start to think about ways to intervene to preserve the function of immune memory cells as we age.'

Read the full paper in Nature Cell Biology.

Read the News & Views in Nature Cell Biology. 

Find out more about the research on the Max Delbrück Center website.

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8th October 2026.

Arthritis origins may begin before birth, study finds

Researchers at the Kennedy Institute have discovered that some joints may be more susceptible to inflammatory arthritis before birth, offering new insight into why rheumatoid arthritis attacks particular joints while sparing others.

Researchers uncover hidden mechanism behind a major cancer therapy target

Kennedy researchers have revealed how one of the immune system's most important regulatory pathways operates at the earliest moments of T cell activation, providing new insights that could help improve cancer immunotherapy.

Pioneering study sets out to answer and address why osteoarthritis impacts patients differently

Researchers from NDORMS are playing leading roles in a major new UK-wide research consortium aiming to improve treatment and outcomes for people living with osteoarthritis.

Largest study of knee osteoarthritis tissue reveals the core biological pathways underlying osteoarthritis

A major international study led by researchers at the Kennedy Institute of Rheumatology at the University of Oxford has found that osteoarthritis (OA) – the most common form of arthritis worldwide – is not a collection of separate diseases, as many scientists had previously speculated, but rather a single condition with common core underlying biological pathways.

Anchoring a key immune molecule boosts T cell responses

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could help explain how immune responses become weakened in cancer and chronic infection and inform the design of more effective vaccines.